A Biotech Wall Around China Would Come at a Cost

American lawmakers are actively pushing companies to divest from China in biotechnology. But cutting US drugmakers off from a fast-growing source of pharmaceutical innovation will prove self-defeating and cede ground to Asian competitors in the race for new medicines.